| Drug ID: | Drug80 |
|---|---|
| Drug Name: | Curcumin |
| CID: | 969516 |
| DrugBank ID: | DB11672 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | NO |
| Other Approved: | NO |
| Identifier: | NCT00889161, , NCT04713631 |
| Molecular Formula: | C21H20O6 |
| Molecular Weight: | 368.4 g/mol |
| Isomeric SMILES: | COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O |
| Synonyms: | curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Kacha haldi; Indian saffron; Gelbwurz; Haldar; Curcumin I; Souchet |
| Phase 0: | 11 |
| Phase 1: | 38 |
| Phase 2: | 67 |
| Phase 3: | 23 |
| Phase 4: | 14 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt675 | 969516 | Curcumin | 4843 | NOS2 | Homo sapiens (human) | None | |
| dt676 | 969516 | Curcumin | 765 | CA6 | Homo sapiens (human) | None | |
| dt677 | 969516 | Curcumin | 1576 | CYP3A4 | Homo sapiens (human) | None | |
| dt678 | 969516 | Curcumin | 4318 | MMP9 | Homo sapiens (human) | None | |
| dt679 | 969516 | Curcumin | 1789 | DNMT3B | Homo sapiens (human) | None | |
| dt680 | 969516 | Curcumin | 1786 | DNMT1 | Homo sapiens (human) | None | |
| dt681 | 969516 | Curcumin | 351 | APP | Homo sapiens (human) | None | |
| dt682 | 969516 | Curcumin | 759 | CA1 | Homo sapiens (human) | None | |
| dt683 | 969516 | Curcumin | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt684 | 969516 | Curcumin | 5594 | MAPK1 | Rattus norvegicus (Norway rat) | 11981161 | Curcumin inhibits the reaction [tetracaine results in increased phosphorylation of MAPK1 protein] |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT02683759 | Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis | PHASE3 | UNKNOWN | Asian Institute of Gastroenterology, India | Ulcerative Colitis | DIETARY_SUPPLEMENT: Bio-enhanced Curcumin Soft Ge… | Details |
| NCT02683733 | Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis | PHASE3 | UNKNOWN | Asian Institute of Gastroenterology, India | Ulcerative Colitis | DIETARY_SUPPLEMENT: Bio-enhanced Curcumin Soft Ge… | Details |
| NCT01320436 | Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis | PHASE3 | COMPLETED | Sheba Medical Center | Ulcerative Colitis | DIETARY_SUPPLEMENT: Curcumin|DRUG: 5-aminosalicyl… | Details |
| NCT03122613 | Curcumin for Prevention of Relapse in Patients With Ulcerative Colitis | None | TERMINATED | Chinese University of Hong Kong | Ulcerative Colitis in Remission | DIETARY_SUPPLEMENT: Curcumin|DRUG: Placebo | Details |
| NCT04713631 | Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease | PHASE2 | RECRUITING | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Crohn's Disease | DRUG: Artesunate|DRUG: Curcumin|DRUG: Placebo A|D… | Details |
| NCT06867939 | A Pilot Study of Curcumin (Soloways in Patients With Inflammatory Bowel Disease Homozygous for the IL-10 Variant | Not Available | Not recruiting | S.LAB (SOLOWAYS) | Inflamatory Bowel Disease | Dietary Supplement: liposomal curcumin;Dietary Su… | Details |
| RBR-89q4ydz | Effect of supplementation with Curcuma Longa (extract) and Piperine on inflammatory markers, oxidative stress and glycoxidation in patients with Inflammatory Bowel Disease treated at a Teaching Hospital in Alagoa | Not Available | Not Recruiting | Universidade Federal de Alagoas | Inflammatory Bowel Disease | This is a double-blind randomized clinical trial.… | Details |
| NCT04879810 | Pilot Clinical Trial Investigating the Ability of Plant Exosomes +/- Curcumin to Abrogate Symptoms of Inflammatory Bowel Disease (IBD) | Not Available | Not recruiting | University of Louisville | Irritable Bowel Disease | Procedure: Sigmoidoscopy and biopsy, blood work | Details |
| JPRN-UMIN000015770 | Randomized double-blind multicenter study for anti-inflammatory effects of highly bioavailable curcumin on Crohn's disease. - Exploratory study for effects of highly bioavailable curcumin on Crohn's disease. | Not Available | Not Recruiting | Hamamatsu South Hospital, Centre for Gastroenterology and Inflammatory Bowel Disease Research | Crohn's disease (180 <= CDAI < 450) … | Standard therapy for Crohn's disease (Pentasa… | Details |
| NCT00889161 | Curcumin in Pediatric Inflammatory Bowel Disease | PHASE1 | COMPLETED | Seattle Children's Hospital | Inflammatory Bowel Disease|Ulcerative Colitis|Cro… | DRUG: Curcumin | Details |
| NCT05761327 | Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis | None | COMPLETED | Ardahan University | Ulcerative Colitis | OTHER: Mediterranean Diet|DIETARY_SUPPLEMENT: Cur… | Details |
| NCT02277223 | Curcumin in Pediatric Ulcerative Colitis | PHASE3 | WITHDRAWN | Schneider Children's Medical Center, Israel | Ulcerative Colitis | DIETARY_SUPPLEMENT: Curcumin|DRUG: Placebo | Details |
| NCT03500653 | Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab | None | UNKNOWN | Henit Yanai | Inflammatory Bowel Diseases | DIETARY_SUPPLEMENT: Curcumin|DIETARY_SUPPLEMENT: … | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| 1.0 | Crohn's disease | An intestinal disease that involves inflammation located_in intestine. | disease of anatomical entity gastrointestinal system disease, intestinal disease, inflammatory bowel disease | Obiltoxaximab; Budesonide; Hydrocortisone acetate; Sulfasalazine; Ursodeoxycholic acid; Pegunigalsidase alfa; Imiglucerase; Bictegravir; Taliglucerase alfa; Etelcalcetide; Cimetidine; Desonide | Crohn's disease is a relapsing systemic inflammatory diseas… | Details |
| 2.0 | ulcerative colitis | A colitis that is predominantly confined to the mucosa located_in colon and includes characteristic ulcers, or open sores. | disease of anatomical entity, gastrointestinal system disease, autoimmune disease of gastrointestinal tract; intestinal disease, inflammatory bowel disease, colitis; disease, primary immunodeficiency disease, autoimmune disease, autoimmune disease of gastrointestinal tract | Mirikizumab; Olsalazine; Balsalazide; Sulfasalazine; Budesonide; Hydrocortisone acetate; Tixocortol; Kappadione; Teicoplanin; Atezolizumab; Gamolenic acid; Upadacitinib | No abstract available | Details |
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S01 | Anti-inflammatory | inflammatory | 5-Aminosalicylates (5-ASAs); corticosteroids | Crohn's disease and ulcerative colitis are the two main com… | Details |
| S02 | Immunosuppression | Classic immunosuppressive drugs | azathioprine; 6-mercaptopurine; methotrexate; ciclosporin-A; tacrolimus | Ciclosporin-A and tacrolimus bind to specific intracellular… | Details |
| S03 | Anti-TNF agents | Tumor necrosis factor | infliximab; adalimumab; golimumab; certolizumab pegol | TNF is produced by various immune and non-immune cells in t… | Details |
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S05 | Angiogenesis | cell proliferation; vascular permeability | ozanimod | The bioactive lipid S1P has been shown to activate NF-κB an… | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
| S08 | Strengthening barrier function | Modulation of barrier function | phosphatidylcholine (lecithin); imiquimod; mongersen | Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negat… | Details |
| S11 | Improveming Intestinal Microecology | the intestinal microbiota | antibiotics; probiotics; prebiotics; postbiotics; synbiotics; fecal microbiota transplantation (FMT) | The imbalance between beneficial bacteria and harmful patho… | Details |
Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerati…
PMID: 26275840
Year: 2015
Relationship Type:
Treatment
Score: 6.3
Oral colon-specific drug delivery is of great interest for ulcerative colitis (UC) therapy. Here, an emulsion-solvent evaporation method was used to …
Curcumin, inflammation, and chronic diseases: how are they linked?
PMID: 26007179
Year: 2015
Relationship Type:
Treatment
Score: 6.3
It is extensively verified that continued oxidative stress and oxidative damage may lead to chronic inflammation, which in turn can mediate most chro…
Curcumin-Zn(II) complex for enhanced solubility and stability: an approach for …
PMID: 25923136
Year: 2016
Relationship Type:
Association
Score: 6.3
OBJECTIVE: The aim of present investigation was to prepare Curcumin-Zn(II) complex in a view to enhance solubility, stability and pharmacodynamic eff…
Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild…
PMID: 25724700
Year: 2015
Relationship Type:
Association
Score: 6.3
Sphingosine kinase 1 (SK1), one of two SK enzymes, is highly regulated and has been shown to act as a focal point for the action of many growth fact…
pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bow…
PMID: 25014369
Year: 2014
Relationship Type:
Association
Score: 6.3
Epidemiologic studies associate low serum vitamin D levels with an increased risk of colon cancer and inflammatory diseases such as inflammatory bow…
pH triggered delivery of curcumin from Eudragit-coated chitosan microspheres fo…
PMID: 24758141
Year: 2016
Relationship Type:
Pharmacology
Score: 6.3
OBJECTIVE: This investigation deals with the development and evaluation (in vitro and in vivo) of pH triggered Eudragit-coated chitosan microspheres …
pH-sensitive nanoparticles of curcumin-celecoxib combination: evaluating drug s…
PMID: 24375287
Year: 2014
Relationship Type:
Treatment
Score: 6.3
Inflammatory bowel diseases, which largely comprise ulcerative colitis (UC) and Crohn's disease, are increasingly posing as a global threat because o…
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose…
PMID: 23059643
Year: 2013
Relationship Type:
Treatment
Score: 6.1
Inflammatory bowel disease (IBD) patients display elevated levels of intraluminal nitric oxide (NO). NO can react with other molecules to form toxic…
Curcumin and inflammatory bowel disease: biological mechanisms and clinical imp…
PMID: 22950087
Year: 2012
Relationship Type:
Treatment
Score: 6.1
Increased recognition of the limits of conventional medicine has helped drive the growing interest in complementary and alternative medicine which is…
Curcumin inhibits interferon-γ signaling in colonic epithelial cells
PMID: 22038826
Year: 2012
Relationship Type:
Treatment
Score: 6.1
Erratum in Aliment Pharmacol Ther. 2012 Apr;35(7):864. Comment in Aliment Pharmacol Ther. 2012 Feb;35(3):391-2; discussion 392-3. BACKGROUN…
Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute sma…
PMID: 21151942
Year: 2010
Relationship Type:
Treatment
Score: 6.1
BACKGROUND: The health beneficial effects of Resveratrol, Curcumin and Simvastatin have been demonstrated in various experimental models of inflammat…
Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular …
PMID: 18596194
Year: 2008
Relationship Type:
Association
Score: 6.1
A mutant strain with defective thymic selection of the Long-Evans Cinnamon (LEC) rat was found to spontaneously develop inflammatory bowel disease (…
Protective effects of dietary curcumin in mouse model of chemically induced col…
PMID: 18200517
Year: 2008
Relationship Type:
Association
Score: 6.1
OBJECTIVES: We analyzed ATG16L1, a recently identified Crohn's disease (CD) susceptibility gene, in a large cohort with inflammatory bowel disease (…
Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats coli…
PMID: 15793857
Year: 2005
Relationship Type:
Treatment
Score: 6.1
BACKGROUND & AIMS: Bone loss is a common complication of human inflammatory bowel disease (IBD), but its mechanisms are not understood completely. W…